We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Donna
Graham
donna.graham8@nhs.net
Subir
Singh
subir.singh@nhs.net
Hannah
Frost
Hannah.frost@cruk.manchester.ac.uk
Malignant neoplasms of respiratory and intrathoracic organsMalignant neoplasms of urinary tractMelanoma and other malignant neoplasms of skin
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Checkpoint inhibitors are immunotherapy drugs that have shown impressive success in treating a range of hard to treat cancers. Treatment related side effects - or immune related adverse events - are often seen with these treatments and are thought to occur in a number of different ways. Treatment will have to be stopped in 20% of patients due to these immune related adverse events, and up to 90% of all patients on checkpoint inhibitors will experience an immune related adverse event.
Cytokines are proteins that are secreted by cells during an inflammatory response. Early evidence suggests that changes in levels of cytokines may differentiate patients who are likely to develop side effects from these treatments from those who do not.
This study will explore the ability of patients on first line combination immunotherapy to sample cytokines at home. The data from this study will be used to evaluate the feasibility of in-home testing and the ability to analyse patients cytokine profiles retrospectively to help feed the development of further studies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Previous immunotherapy (including any CPI either as single agent on in combination or high dose interleukin-2). 2. Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements. 3. Consideration should be given to the exclusion of patients who are on long-term anti-coagulants, if deemed by the clinician to be at risk from daily finger pricking.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Hannah
Frost
Hannah.frost@cruk.manchester.ac.uk
Subir
Singh
subir.singh@nhs.net
Donna
Graham
donna.graham8@nhs.net
The study is sponsored by THE CHRISTIE NHS FOUNDATION TRUST and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49239
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
